ResearcherYeditepe UniversityActive in the last 2 years

Dilek Telci

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2793-6533; OpenAlex author ID A5010755529. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 2

In Vitro Evidence for the Dual Antioxidant and Anti-Inflammatory Roles of Hypericum triquetrifolium in Cancer Therapy: Selective Cytotoxicity Against Pancreati… Co-author DOI 10.3390/molecules31101628 ↗
Palbociclib, a selective CDK4/6 inhibitor, restricts cell survival and epithelial-mesenchymal transition in Panc-1 and MiaPaCa-2 pancreatic cancer cells. Last author DOI 10.1002/jcb.29249 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Hande Si̇pahi̇ · 1 shared paper, 2026 · strength 0.32
- Paper In Vitro Evidence for the Dual Antioxidant and Anti-Inflammatory Roles of Hypericum triquetrifolium in Cancer Therapy: … DOI 10.3390/molecules31101628 ↗
Ece Sabuncu · 1 shared paper, 2026 · strength 0.32
- Paper In Vitro Evidence for the Dual Antioxidant and Anti-Inflammatory Roles of Hypericum triquetrifolium in Cancer Therapy: … DOI 10.3390/molecules31101628 ↗
Pınar Obakan Yerlikaya · 1 shared paper, 2020 · strength 0.15
- Paper Palbociclib, a selective CDK4/6 inhibitor, restricts cell survival and epithelial-mesenchymal transition in Panc-1 and … DOI 10.1002/jcb.29249 ↗
Özge Rencüzoğulları · 1 shared paper, 2020 · strength 0.15
- Paper Palbociclib, a selective CDK4/6 inhibitor, restricts cell survival and epithelial-mesenchymal transition in Panc-1 and … DOI 10.1002/jcb.29249 ↗
Elif Damla Arısan · 1 shared paper, 2020 · strength 0.15
- Paper Palbociclib, a selective CDK4/6 inhibitor, restricts cell survival and epithelial-mesenchymal transition in Panc-1 and … DOI 10.1002/jcb.29249 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.